Globus Medical, Inc. is a medical device company that develops and sells healthcare solutions for musculoskeletal disorders. Its primary customers include hospitals, surgical centers, and healthcare providers in the United States and internationally. Revenue is generated from a range of products, including spine products (approximately 50%), orthopedic trauma solutions (about 30%), and biologic products (around 20%). Factors supporting the company's endurance include the growing demand for innovative medical devices and advancements in surgical techniques. However, competition from other medical device manufacturers and potential regulatory challenges could limit its growth prospects.
—
Globus Medical, Inc. is a medical device company that develops and sells healthcare solutions for musculoskeletal disorders. Its primary customers include hospitals, surgical centers, and healthcare providers in the United States and internationally. Revenue is generated from a range of products, including spine products (approximately 50%), orthopedic trauma solutions (about 30%), and biologic products (around 20%). Factors supporting the company's endurance include the growing demand for innovative medical devices and advancements in surgical techniques. However, competition from other medical device manufacturers and potential regulatory challenges could limit its growth prospects.
—
Daily adjusted close
Globus Medical, Inc. is a medical device company that develops and sells healthcare solutions for musculoskeletal disorders. Its primary customers include hospitals, surgical centers, and healthcare providers in the United States and internationally. Revenue is generated from a range of products, including spine products (approximately 50%), orthopedic trauma solutions (about 30%), and biologic products (around 20%). Factors supporting the company's endurance include the growing demand for innovative medical devices and advancements in surgical techniques. However, competition from other medical device manufacturers and potential regulatory challenges could limit its growth prospects.